DNA plasmid production in different host strains of Escherichia coli
- 347 Downloads
We compared plasmid DNA production in 13 strains of Escherichia coli in shake flasks using media containing glucose or glycerol. DNA yield from either carbon source showed small correlation with maximum growth rate. Three strains, SCS1-L, BL21 and MC4100, were selected for a controlled exponential fed-batch process at a growth rate of 0.14 h−1 to an optical density of about 70, followed by a four-hour heat treatment. Prior to heat treatment, SCS1-L generated 15.4 mg DNA/g, BL21 generated 11.0 mg DNA/g and MC4100 generated 7.9 mg DNA/g, while after heat treatment the strains attained DNA yields, respectively, of 18.0, 15.0 and 6.8 mg/g. The strains also varied in their percentage of supercoiled DNA after heat treatment, with SCS1-L averaging 66% supercoiled, BL21 17% and MC4100 40%. We further investigated the two strains that yielded the highest percentage of supercoiled DNA (SCS1-L and MC4100) at a higher growth rate of 0.28 h−1. At this condition, a slightly lower DNA yield was generated faster, and the percentage of supercoiled DNA increased. Heat treatment improved DNA yield, and surprisingly did so to a greater extent at the higher growth rate. As a consequence of these factors, higher growth rates might be advantageous for DNA production.
KeywordsFed-batch process Supercoiled DNA DNA yield Heat treatment
The authors acknowledge S. E. Kushner at the University of Georgia for helpful advice, and Amanda Randall at Merial for help with the supercoiling analyses.
- 4.Carnes AE (2005) Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Intl 3:36–44Google Scholar
- 6.Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS (2007) Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25:4085–4092. doi: 10.1016/j.vaccine.2007.02.050 PubMedCrossRefGoogle Scholar
- 15.Glaser V (1997) Promise of gene therapy for treating disease remains on trial in the clinic. Genet Eng News 14:33–34Google Scholar
- 17.Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 7:1205–1217. doi: 10.1089/hum.1996.7.10-1205 PubMedCrossRefGoogle Scholar
- 20.Jones RC, Anthony RM (1977) The relationship between nutrient feed rate and specific growth rate in fed batch cultures. Appl Microbiol Biotechnol 4:87–92Google Scholar
- 28.Miki T, Yasukochi T, Nagatani H, Furuno M, Orita T, Yamada H, Imoto T, Horiuchi T (1987) Construction of a plasmid vector for the regulatable high level expression of eukaryotic genes in Escherichia coli: an application to overproduction of chicken lysozyme. Protein Eng 1:327–332. doi: 10.1093/protein/1.4.327 PubMedCrossRefGoogle Scholar
- 36.Rozkov A, Avignone-Rossa CA, Ertl PF, Jones P, O’Kennedy RD, Smith JJ, Dale JW, Bushell ME (2006) Fed batch culture with declining specific growth rate for high-yielding production of a plasmid containing a gene therapy sequence in Escherichia coli DH1. Enzyme Microb Technol 39:47–50. doi: 10.1016/j.enzmictec.2005.09.005 CrossRefGoogle Scholar
- 37.Schmidt T, Friehs K, Flaschel E, Schleef M (2003) Method for the isolation of plasmid DNA. US Patent 6,664,078Google Scholar
- 41.Sheets RL, Stein J, Manetz S, Duffy D, Nason M (2006) Biodistribution of DNA plasmid vaccines against HIV-1, ebola severe acute respiratory syndrome, or west Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 91:610–619. doi: 10.1093/toxsci/kfj169 PubMedCrossRefGoogle Scholar
- 47.US Dept of Health and Human Services, Food and Drug Administration (2007) Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications, November 2007Google Scholar